Julie H. Oestreich - Concepedia

Author

Julie H. Oestreich

University of Kentucky ORCID

Also Known As

J. Oestreich, Julie H Oestreich, Julie H. Oestreich, Julie Oestreich

Publications

1.1K

Citations

H-Index

Concepts

All Affiliations

University of Kentucky University of Nebraska Medical Center Lipscomb University

About

Julie H. Oestreich is an author at University of Kentucky specializing in medicine, pharmacology, and pharmacotherapy.

Top Concepts

#	Concept	H-Index	Publications	Citations
1	Medicine	8	8	728
2	Health Sciences	1	1	10
3	Public Health	1	1	16
4	Cardiothoracic Surgery	1	1	288
5	Emergency Medicine	1	1	288

Julie H. Oestreich

Publications

740

Citations

H-Index

Page 1

	Year	Citations
2012 Update to The Society of Thoracic Surgeons Guideline on Use of Antiplatelet Drugs in Patients Having Cardiac and Noncardiac Operations Victor A. Ferraris, Sibu P. Saha, Julie H. Oestreich, The Annals of Thoracic Surgery Cardiac SurgeryThrombosisCardiac AnaesthesiaCardiothoracic SurgeryPatients Having Cardiac	2012	288
Pharmacokinetics and Pharmacodynamics of a Bolus and Infusion of Cangrelor: A Direct, Parenteral P2Y12 Receptor Antagonist Wendell S. Akers, Jennifer J. Oh, Julie H. Oestreich, The Journal of Clinical Pharmacology ThrombopoiesisThrombosisPharmacological StudyCardiovascular DiseaseBlood Platelet	2009	168
Transitioning patients from cangrelor to clopidogrel: Pharmacodynamic evidence of a competitive effect Steven R. Steinhubl, Jennifer J. Oh, Julie H. Oestreich, Thrombosis Research PharmacologyClinical PharmacologyCompetitive EffectPharmacotherapyPlatelet Antagonist	2007	165
Elinogrel, a reversible P2Y12 receptor antagonist for the treatment of acute coronary syndrome and prevention of secondary thrombotic events. Julie H. Oestreich PubMed Cardiovascular PharmacologyPharmacotherapySingle-dose ElinogrelAcute Myocardial InfarctionThrombosis	2010	31
SCH-530348, a thrombin receptor (PAR-1) antagonist for the prevention and treatment of atherothrombosis. Julie H. Oestreich PubMed PharmacotherapyPlatelet AggregationMolecular PharmacologyThrombosisPhase Iii Trials	2009	30
Recommended Basic Science Foundation Necessary to Prepare Pharmacists to Manage Personalized Pharmacotherapy Larisa H. Cavallari, Brian R. Overholser, Douglas C. Anderson, Pharmacotherapy The Journal of Human Pharmacology and Drug Therapy Patient SelectionPharmacotherapyGenetic MedicineClinical GeneticsPre-clinical Pharmacology	2010	20
Prevalence of CYP2C19 variant alleles and pharmacodynamic variability of aspirin and clopidogrel in Native Americans Julie H. Oestreich, Lyle G. Best, Paul P. Dobesh American Heart Journal Allelic VariantMedicineGenetic EpidemiologyHuman PolymorphismPharmacodynamic Variability	2013	16
Considerable variability in platelet activity among patients with coronary artery disease in response to an increased maintenance dose of clopidogrel Julie H. Oestreich, John M. Holt, Steven P. Dunn, Coronary Artery Disease	2009	12
Effect of genetic variation in P2Y12 on TRAP-stimulated platelet response in healthy subjects Julie H. Oestreich, Steven R. Steinhubl, Suellen P. Ferraris, Journal of Thrombosis and Thrombolysis ThrombopoiesisThrombosisHealthy SubjectsBlood PlateletTrap-stimulated Platelet Response	2014	10

Page 1